dr. subbiah on the fda approval of pralsetinib in ret nsclc
Published 4 years ago • 336 plays • Length 1:07Download video MP4
Download video MP3
Similar videos
-
58:12
pralsetinib for advanced or metastatic ret-altered thyroid cancer with dr. vivek subbiah
-
7:02
fda approval of selpercatinib for ret fusion positive nsclc and thyroid cancers
-
1:46
dr wirth on the full fda approval of selpercatinib for advanced ret fusion thyroid cancer
-
1:14
dr. subbiah on safety and efficacy of blu-667 in ret-altered solid tumors
-
2:07
dr. subbiah on the importance of tivozanib in rcc
-
6:10
the future of ret inhibition in clinical practice
-
58:32
precision oncology with dr vivek subbiah
-
59:44
synthetic control arms and the regulatory maze
-
1:33
dr. chaft on the rise of immunotherapy in lung cancer
-
5:00
dr. vivek subbiah discusses the novel lesion selection tool reported in jipo by xu et al
-
3:58
libretto-001: targeting ret fusions in advanced-stage nsclc
-
6:01
fda d.i.s.c.o.: osimertinib for non-small cell lung cancer
-
3:49
ret fusion treatment: selpercatinib - targeted therapies in lung cancer 2023
-
6:09
ret inhibition in ret aberrant cancers
-
3:05
dr. drilon discusses the results of the phase i/ii libretto-001 trial
-
1:48
dr. chow on the use of ceritinib in alk nsclc metastatic to the brain
-
2:17
learn about the fda approval of larotrectinib
-
1:10
dr besse on mechanisms of acquired resistance in egfr advanced nsclc
-
4:45
ntrk fusions in thyroid cancer